Colleen Cutcliffe is the CEO and Co-Founder of Pendulum Therapeutics. Pendulum is a startup company based in San Francisco that uses biological and computational insights into the microbiome to develop interventions for a variety of health and disease conditions. Using this discovery platform, Pendulum has created the world’s first microbiome intervention for people with Type 2 Diabetes that has been clinically shown to reduce A1C and postprandial glucose response. Colleen has over 20 years of experience managing and leading teams in biotech, pharma and academia. Before starting Pendulum, Colleen served as the Senior Manager of Biology at Pacific Biosciences, which is where she met her two co-founders. Prior to that, Colleen was a Scientist at Elan Pharmaceuticals. Colleen completed her postdoctoral research at Northwestern’s Children’s Memorial Hospital, received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and received her B.A. in Biochemistry from Wellesley College. Colleen currently resides in Menlo Park, CA with her husband, 2 daughters, 2 dogs, and 2 birds and 2 chinchillas...all contributing to a diverse microbiome!